Heterozygous familial hypercholesterolemia

Disease3 papers

Trial sponsors

Regeneron
Company4 trialsPhase 41,758 people
Novartis
Company2 trialsPhase 33,587 people
The Medicines Company
Company1 trialPhase 3482 people
Amgen
Company1 trialPhase 3158 people
Madrigal Pharmaceuticals
Company1 trialPhase 2116 people

Latest

6

The Annals of PharmacotherapyReview26 Sep

Lerodalcibep-liga as an Injectable Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Targeted Therapy for Patients With Hypercholesterolemia

Hypercholesterolemia

Journal of Cardiovascular MedicineReview21 Sep

Dose-stratified lipid-lowering efficacy and safety of oral PCSK9 inhibitors: a systematic review and meta-analysis

Expert Opinion on PharmacotherapyReview8 Sep

Evaluating enlicitide decanoate: first oral PCSK9 inhibitor for the treatment of adults with hypercholesterolemia

Hypercholesterolemia

Journal of Cardiovascular Development and DiseaseReview26 Aug

Enlicitide, a Novel Oral Macrocyclic Peptide PCSK9 Inhibitor for Lipid Lowering: A Systematic Review and Meta-Analysis

AHA Scientific Sessions 2025 AbstractReview3 Nov

Efficacy of Bempedoic Acid Versus Placebo for Additional Lipid Lowering in Patients Receiving Background Statin Therapy: A Meta-Analysis of Randomized Controlled Trials

AHA Scientific Sessions 2025 AbstractHumans3 Nov

Protein-Truncating Variants of the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Artery Disease among Patients with Heterozygous Familial Hypercholesterolemia